Split designed to achieve compliance with Nasdaq minimum bid price requirementsBOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price ...

Financial Data and Key Metrics Changes - The proposal for a reverse stock split has been approved by a majority of votes, indicating a strategic move to potentially enhance the stock price and attract more investors [6] - The adjournment proposal was also approved, allowing for further solicitation of proxies if necessary [6] Business Line Data and Key Metrics Changes - No specific financial data or performance metrics for individual business lines were provided during the meeting [7] Market Data and Key Metrics Changes - There was no detailed market data or key metrics discussed in the meeting [7] Company Strategy and Development Direction - The company is focused on clinical trials and is committed to reporting data as it becomes available, emphasizing transparency in their research process [8] - The management is preparing to draw down NIH grant funding in the foreseeable future, indicating ongoing reliance on external funding sources [9] Management Comments on Operating Environment and Future Outlook - Management has not experienced adverse effects from NIH grant funding cuts to date, but they are cautious about future implications [9] - The company is optimistic about the nature of their grant and the timing, although uncertainties remain [9] Other Important Information - The meeting concluded with a commitment to report clinical trial data as expeditiously as possible, highlighting the importance of quality control and safety review processes [8] Q&A Session Summary Question: How often are clinical trial assessments done during the current clinical study? - Management stated that they report data as soon as it is available, emphasizing the need for quality control and committee checks before publishing results [8] Question: Has your NIH grant funding been affected by the recent funding cuts? - Management confirmed that there have been no adverse effects from NIH grant funding so far, but they are preparing to draw down funds soon, with future implications still uncertain [9]

A total of 13 patients treated with four escalating doses of TTX-MC138 No significant safety or dose limiting toxicities reported Two patients have so far maintained stable disease on treatment for at least seven months PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagementBOSTON, May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress ...

Core Viewpoint - TransCode Therapeutics Inc. (RNAZ) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [2][4]. - Rising earnings estimates for TransCode Therapeutics suggest an improvement in the company's underlying business, likely leading to increased stock prices [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - The upgrade of TransCode Therapeutics to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, TransCode Therapeutics is expected to earn -$1.63 per share, reflecting a 96.5% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for TransCode has increased by 62.7%, highlighting a positive trend in earnings estimates [8].

Financial Position and Capital Requirements - As of December 31, 2024, the company had cash of approximately $5.8 million, which is expected to support operating expenses into the middle of Q2 2025[287]. - The company incurred net losses of approximately $16.8 million and $18.5 million for the years ended December 31, 2024, and 2023, respectively, with an accumulated deficit of approximately $63.2 million as of December 31, 2024[289]. - The company plans to raise additional capital to continue operations, with a net proceeds expectation of approximately $8.8 million from equity financing completed on March 25, 2025[296]. - Future capital requirements will depend on various factors, including the costs of drug discovery, clinical trials, and regulatory reviews[299]. - The company anticipates ongoing significant losses and may not achieve profitability in the foreseeable future due to the speculative nature of oncology product development[288]. - The company may need to seek in-court or out-of-court restructuring of liabilities if unable to raise sufficient capital, which could lead to a total loss of investment for stockholders[287]. Clinical Development and Regulatory Challenges - The company has completed a Phase 0 clinical trial and initiated a Phase I/II study, successfully enrolling 10 patients in four treatment cohorts[288]. - TTX-MC138 is undergoing an open Phase I/II clinical trial designed to assess safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity[323]. - The company has not yet demonstrated the ability to successfully complete clinical trials or obtain marketing approvals for any therapeutic candidates[305]. - The clinical development process is lengthy, complex, and expensive, with no assurance of success[322]. - The company faces significant uncertainties regarding the timing and success of clinical trials, regulatory approvals, and market demand for its therapeutic candidates[304]. - The success of TTX-MC138 is critical, as the company currently has no products approved for commercial sale[315]. - The company must navigate various risks, including competition, regulatory barriers, and the potential for undesirable side effects from its therapeutic candidates[319]. - The results of preclinical studies and early-stage clinical trials may not predict later-stage outcomes, leading to potential setbacks in development[322]. - Successful completion of clinical trials is a prerequisite for submitting marketing applications to the FDA and comparable foreign regulatory authorities[329]. - The company may experience negative or inconclusive results in clinical trials, potentially leading to additional studies or abandonment of product development programs[330]. - The company faces challenges in patient enrollment for clinical trials, which could delay development activities and increase costs[336]. - Quality issues could delay or prevent the delivery of products to clinical trials or the market, impacting regulatory approval[348]. - The company must comply with FDA's good clinical practice and current good manufacturing practice regulations[350]. - The company has received Orphan Drug Designations for TTX-MC138 and TTX-siPDL1 for pancreatic cancer, which may provide market exclusivity benefits[371]. - The FDA may grant Orphan Drug Exclusivity for a product if it is the first to receive approval for a specific disease, preventing other applications for the same indication for seven years[373]. - The company has limited experience in conducting clinical trials necessary for regulatory approvals, which may lead to unpredictable delays[359]. - Regulatory approval processes can vary significantly between the FDA and foreign authorities, potentially impacting the timeline for commercialization[367]. - The FDA's review timelines for New Drug Applications (NDAs) are flexible and can be extended based on workload, which may delay product approvals[364]. - The company may encounter unexpected delays or increased costs due to changes in government regulations or FDA policies during product development[361]. - Regulatory approvals may require costly post-marketing studies and compliance with ongoing requirements[389]. - Failure to comply with regulatory requirements may result in penalties or withdrawal of product approvals[390]. Market and Competitive Landscape - The company faces substantial competition from major biotechnology firms and academic institutions, which may impact its market position[433]. - Mergers and acquisitions in the biopharmaceutical industry could concentrate resources among competitors, increasing competitive pressures[436]. - The company currently lacks a marketing and sales organization, which may hinder its ability to generate product revenue if regulatory approvals are obtained[422]. - Coverage and reimbursement from third-party payors are critical for the commercial success of therapeutic candidates, with significant uncertainty regarding their availability[424]. - The company faces a lengthy sales cycle influenced by market conditions, perceived value of products, and competition, which may adversely affect market acceptance[440]. - The company is dependent on third-party organizations for conducting preclinical studies and clinical trials, which may lead to delays in obtaining regulatory approval[448]. Operational and Organizational Challenges - The company may encounter unforeseen expenses and complications as it transitions from a research-focused entity to one capable of supporting commercial activities[308]. - The company has moved its laboratory operations to new facilities, including a sublease in Newton, Massachusetts, which may affect R&D access[464]. - The company relies heavily on third-party services, and any disruption in these services could delay clinical trials and regulatory approvals[470]. - Failure to effectively expand the organization may hinder the development and commercialization of therapeutic candidates[471]. - Retaining key executives and attracting qualified personnel is critical for success in the competitive oncology industry[472]. - The company faces intense competition for hiring qualified personnel, which may impede research and development objectives[475]. Regulatory and Legislative Environment - Legislative changes, such as the ACA, have significantly impacted the U.S. biotechnology and biopharmaceutical industries, including increased Medicaid rebates and new Medicare discount programs[401]. - The company may experience pricing pressures due to legislative measures aimed at controlling pharmaceutical pricing and reimbursement levels[409]. - The Budget Control Act of 2011 triggered automatic reductions to Medicare payments, which could affect the company's revenue from government programs[403]. - The company is subject to U.S. and foreign trade laws, with violations potentially resulting in substantial fines, penalties, and reputational harm[410]. - Ongoing healthcare reform efforts may materially affect the company's revenue prospects and operational strategies[412]. - The ACA has introduced many programs and requirements that are still not fully understood, posing risks to reimbursement and operational volumes[414]. - The company anticipates that future healthcare reforms may lead to further reductions in Medicare and other healthcare funding, affecting pricing and demand for its products[409]. - The Inflation Reduction Act of 2022 allows CMS to negotiate prices for certain high-cost drugs under Medicare, starting with ten drugs in 2026 and increasing to 20 drugs by 2029[415]. - Medicare beneficiaries' annual out-of-pocket drug expenses are capped at $2,000, which may impact the company's pricing strategies[416]. - The expansion of group purchasing organizations and integrated delivery networks is expected to increase pricing pressure on approved products[420]. Risk Management and Compliance - The company may face substantial liabilities from product liability claims, which could inhibit the commercialization of its therapeutic candidates[357]. - The company may not obtain sufficient product liability insurance, which could further hinder the commercialization of its products[357]. - The company must navigate a complex regulatory landscape, with potential changes in healthcare spending and policies impacting its business[412]. - Compliance with animal welfare regulations could increase operating costs and impact product commercialization[478]. - The ability to utilize net operating loss carryforwards may be limited by ownership changes, potentially affecting future tax liabilities[479].

First patient in Cohort four has been treated with TTX-MC138 Ten patients have been treated with TTX-MC138 at escalating dose levels Additional patients being evaluated for eligibility for expanded enrollment No significant safety or dose limiting toxicities have been reportedBOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of i ...

Company Overview - TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics [5] - The company's lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [5] - TransCode has a portfolio of first-in-class RNA therapeutic candidates designed to improve RNA delivery and access novel genetic targets for cancer treatment [5] Recent Offering - The company announced the closing of a sale of 10,250,000 shares of common stock and warrants, generating gross proceeds of approximately $10 million at a price of $0.98 per share [1][2] - Proceeds from the offering will primarily be used for product development activities, including clinical trials for TTX-MC138 and general corporate purposes [2] - ThinkEquity acted as the sole placement agent for the offering [2] Regulatory Compliance - The offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3] - The final prospectus supplement related to the offering is available on the SEC's website [3]

Core Viewpoint - TransCode Therapeutics, Inc. has announced a public offering of 10,250,000 shares of common stock and warrants, aiming to raise approximately $10 million for product development and working capital [1][2]. Group 1: Offering Details - The shares are priced at $0.98 each, with warrants having an exercise price of $0.86, immediately exercisable for five years [1]. - The offering is expected to close on March 25, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to product development activities, including clinical trials for TTX-MC138, the company's lead therapeutic candidate, and for general corporate purposes [2]. Group 3: Company Overview - TransCode is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics, utilizing its proprietary TTX nanoparticle platform [6]. - The lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis [6].

Core Insights - TransCode Therapeutics has received unanimous approval from the Safety Review Committee (SRC) to open the fourth cohort of its Phase I clinical trial for TTX-MC138, a first-in-class RNA therapeutic targeting metastatic cancers [1][3] - The fourth cohort will receive a dose approximately fifty percent higher than that administered in the third cohort, indicating a planned escalation in dosage [1][2] - The trial has shown no dose limiting toxicities or disease progression in the first three cohorts, with six out of nine patients continuing treatment [2][7] Company Overview - TransCode Therapeutics is focused on developing RNA therapeutics for cancer treatment, particularly targeting metastatic diseases through its proprietary TTX nanoparticle platform [8] - TTX-MC138 specifically targets microRNA-10b, which is associated with metastatic disease, and has shown promising results in preclinical and early clinical trials [4][8] Clinical Trial Details - The Phase I clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study aimed at evaluating the safety and tolerability of TTX-MC138 in patients with various metastatic solid cancers [5] - The trial consists of an initial dose-escalation stage followed by a dose-expansion stage, with the primary objective of assessing safety and tolerability [5] - Preliminary pharmacokinetic (PK) and pharmacodynamic (PD) analyses from Cohorts 1 and 2 are consistent with preclinical results, suggesting an efficacious dose range of 0.8-1.6 mg/kg [2][7]

Company Overview - TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease using RNA therapeutics [3] - The company utilizes its proprietary TTX nanoparticle platform for the intelligent design and effective delivery of RNA therapeutics [3] - The lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [3] - TransCode has a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for various cancers [3] Special Meeting Outcomes - The Special Meeting held on February 25, 2025, resulted in the approval of two proposals by a majority of votes cast [5] - Proposal One involved the approval of the full issuance of shares of Common Stock upon the exercise of Series C and Series D Warrants, adjustments to the exercise price, and an alternative cashless exercise feature [5] - Proposal Two allowed for the adjournment of the Special Meeting to solicit further votes if necessary, which was also approved by a majority [5]